Sri International

Daikin Industries, Ltd.

Colby Pharmaceutical Company

Pangene Corporation

Other

The Medical College of Wisconsin, Inc.

Invitrogen Corporation

Orasure Technologies, Inc.

Sri, Inc.

David A Zarling

James G Kane

Norman A Peppers

Luke V Schneider

Mark J Dyer

Steve Y Ng

Gregory W Faris

Michel J Rossi

Elissa P Sena

Sushma Pati

Cornelia J Calhoun

R Sam Niedbala

Keith W Kardos

David E Cooper

Hirak S Basu

Gurucharan Reddy

Hong Zeng

Jarrett Lee Burton

Balaraman Kalyanaraman

George Wilding

Christopher J Green

Joy Joseph

Anne Vallerga

Boris Belotserkovskii

Dawn R Church

Farideh Mehraein-Ghomi

Described herein are pharmaceutical compositions and medicaments, and methods of using such pharmaceutical compositions and medicaments in the treatment of cancer.

Androgen induced oxidative stress inhibitors

The inventions disclosed include methods of treating cancers and related neoplasias, especially prostate cancer, with pharmaceutically acceptable salts comprising lipophilic cation moieties linked to nitroxide or linked to hydroxylamine anti-oxidant groups.

Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers

The invention relates to methods for inhibiting, cloning, modifying or labelling an endogenous DNA sequence using compositions comprising recombinases in combination with exogenous polynucleotides containing 'anchoring' or 'locking' sequences. The anchoring sequences serve to stabilize structures formed by the exogenous polynucleotides and the endogenous DNA. The stabilized structure thus can either serve to regulate gene transcription or replication, or can allow the endogenous sequences to be labelled or pulled out, i.e. cloned, or modified.

Locked nucleic acid hybrids and methods of use

Provided herein are methods for inhibiting cell proliferation in an individual comprising administering to the individual a composition comprising a Rad51 inhibitor. Also provided herein is a method for inhibiting the growth of a cell comprising administering to said cell a composition comprising a Rad51 inhibitor. Such methods can further include the step of providing radiation or DNA damaging agents after administration of said Rad51 inhibitor. Also described herein are methods which are performed in vivo and/or on cancerous cells.

Antisense inhibition of RAD51

The invention provides methods, compositions, and apparatus for performing sensitive detection of analytes, such as biological macromolecules and other analytes, by labeling a probe molecule with an up-converting label. The up-converting label absorbs radiation from an illumination source and emits radiation at one or more higher frequencies, providing enhanced signal-to-noise ratio and the essential elimination of background sample autofluorescence. The methods, compositions, and apparatus are suitable for the sensitive detection of multiple analytes and for various clinical and environmental sampling techniques.

Up-converting reporters for biological and other assays using laser excitation techniques

The invention relates to compositions and methods for targeting sequence modifications in one or more genes of a related family of genes using enhanced homologous recombination techniques. These techniques may be used to create animal or plant models of disease as well as to identify new targets for drug or pathogen screening.

Use of consensus sequences for targeted homologous gene isolation and recombination in gene families

Up-converting reporters for biological and other assays

The invention relates to methods for targeting an exogenous polynucleotide or exogenous complementary polynucleotide pair to a predetermined endogenous DNA target sequence in a eukaryotic cell by homologous pairing, particularly for altering an endogenous DNA sequence, such as a chromosomal DNA sequence, typically by targeted homologous recombination. In certain embodiments, the invention relates to methods for targeting an exogenous polynucleotide having a linked chemical substituent to a predetermined endogenous DNA sequence in a metabolically active eukaryotic cell, generating a DNA sequence-specific targeting of one or more chemical substituents in an intact nucleus of a metabolically active eukaryotic cell, generally for purposes of altering a predetermined endogenous DNA sequence in the cell. The invention also relates to compositions that contain exogenous targeting polynucleotides, complementary pairs of exogenous targeting polynucleotides, chemical substituents of such polynucleotides, and recombinase proteins used in the methods of the invention.

Homologous sequence targeting in eukaryotic cells

The invention relates to methods for targeting an exogenous polynucleotide or exogenous complementary polynucleotide pair to a predetermined endogenous DNA target sequence in a target cell by homologous pairing, particularly for altering an endogenous DNA sequence, such as a chromosomal DNA sequence, typically by targeted homologous recombination. In certain embodiments, the invention relates to methods for targeting an exogenous polynucleotide having a linked chemical substituent to a predetermined endogenous DNA sequence in a metabolically active target cell, generating a DNA sequence-specific targeting of one or more chemical substituents in an intact nucleus of a metabolically active target cell, generally for purposes of altering a predetermined endogenous DNA sequence in the cell. The invention also relates to compositions that contain exogenous targeting polynucleotides, complementary pairs of exogenous targeting polynucleotides, chemical substituents of such polynucleotides, and recombinase proteins used in the methods of the invention.

Sequence alterations using homologous recombination

Up-converting reporters for biological and other assays using laser

In vivo homologous sequence targeting in eukaryotic cells

Growing community of inventors

Menlo Park, CA, United States of America

David A Zarling